JP-2266 / Jeil - LARVOL DELTA

Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study. (PubMed, Diabetes Metab J) - P2 | "In patients with T2DM inadequately controlled by lifestyle alone, JP-2266 significantly improved glycemic control, reduced body weight and blood pressure, and was well tolerated over 12 weeks. These findings support further investigation of JP-2266 as a potential therapeutic option for T2DM."

Clinical • Journal • P2 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients (clinicaltrials.gov) - P2 | N=161 | Completed | Sponsor: Jeil Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients (clinicaltrials.gov) - P2 | N=156 | Not yet recruiting | Sponsor: Jeil Pharmaceutical Co., Ltd.

Trial completion date • Trial initiation date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus